Supernus Pharmaceuticals (SUPN) Other Operating Expenses (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Other Operating Expenses data on file, last reported at $65.3 million in Q4 2025.

• Other Operating Expenses for Q4 2025 came in at $65.3 million, up 46.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $146.2 million (down 7.23% YoY), and the FY2025 annual result was $189.4 million, up 26.48% from the prior year.
• Other Operating Expenses rose to $65.3 million in Q4 2025 per SUPN's latest filing, from $43.3 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $65.3 million in Q4 2025 and troughed at $22.2 million in Q2 2021.
• A 5-year average of $40.6 million and a median of $41.3 million in 2021 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2021 and 2024: Other Operating Expenses surged 662.26% in 2021, then declined 26.34% in 2024.
• A 5-year view of Other Operating Expenses shows it stood at $30.1 million in 2021, then soared by 36.86% to $41.2 million in 2022, then surged by 47.11% to $60.7 million in 2023, then declined by 26.34% to $44.7 million in 2024, then jumped by 46.07% to $65.3 million in 2025.
• Business Quant data shows SUPN's Other Operating Expenses at $65.3 million in Q4 2025, $43.3 million in Q3 2025, and $37.6 million in Q2 2025.